在CDK12抑制剂的结构类型和药理学方面的进展
Dan Wang1, Ming-Tao Xia1, Jia-Xin Yan1
1Key Laboratory of Traditional Chinese Medicine Research and Development of Hebei Province, Institute of Traditional Chinese Medicine, Chengde Medical University, Chengde 067000, P.R. China.
Medicinal chemistry (Shariqah (United Arab Emirates))
|January 24, 2025
概括
循环素依赖性激酶 (CDK) 12对于DNA修复和基因转录至关重要. 本综述详细介绍了自2020年以来的新型CDK12抑制剂,分析了它们的结构,临床潜力和癌症治疗的未来发展.
科学领域:
- 分子生物学分子生物学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 循环素依赖性激酶 (CDK) 12调节基因转录,DNA损伤反应 (DDR) 和其他重要的细胞过程.
- CDK12是各种癌症的新兴治疗点,包括前列腺癌,乳腺癌和卵巢癌.
- 开发选择性CDK12抑制剂是具有挑战性的,因为它与其他CDK具有很高的同质性,例如CDK13.
研究的目的:
- 审查自2020年以来报告的新型CDK12抑制剂.
- 分析这些抑制剂的结构特征和生物活性.
- 总结CDK12抑制剂的临床应用潜力,挑战和未来趋势.
主要方法:
- 科学出版物和专利的文献评论.
- 报告的CDK12抑制剂的结构分析.
- 评估生物活动和临床数据.
主要成果:
- 各种新型CDK12抑制剂的识别和总结.
- 对所选抑制剂的结构-活性关系的分析.
- 概述目前CDK12抑制剂开发的现状.
结论:
- 在开发新型CDK12抑制剂方面取得了重大进展.
- 在实现选择性和推进临床应用方面仍然存在挑战.
- 未来的研究应该专注于克服这些挑战,以获得有效的癌症疗法.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Anaphase Promoting Complex
2.8K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.8K
Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


